Epetraborole’s potent activity against M. abscessus supports further investigation as a potential therapy for disease with an estimated all-cause mortality of 45% AN2 Therapeutics, Inc. (Nasdaq: ANTX) ...
Epetraborole’s potent activity against M. abscessus supports further investigation as a potential therapy for disease with an estimated all-cause mortality of 45% ...
AN2 Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. AN2 has a pipeline of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback